Grant: CIHR Fellowship
McGill University
$45,000.00
Leveraging ventral striatal signatures of behavioural disengagement to treat binge-eating disorder
EF 2023-24
Résumé
People with Binge Eating Disorder (BED), the most common eating disorder, perform longer bouts of eating than is necessary, causing myriad negative health consequences. How the brain controls the durations of bouts of eating is unknown and BED treatments are crude, commonly using antidepressants to address comorbidities rather than BED itself. Dopamine activity in the ventral striatum (VS) powerfully reinforces behaviour, influences food cravings, and is disrupted in BED. If we understood the profiles of activity in dopamine type-1 (D1) and type-2 (D2) neurons within the VS that control eating duration, we could recapitulate these activity signatures to promote healthy eating and treat BED. First, we will allow mice to directly stimulate dopamine activity in the VS and use pharmacology to examine whether D1 or D2 activity disengages this behaviour. Then, we will record the calcium activity of individual cells in the VS while mice consume bittersweet solutions to discover patterns of activity that promote long (more sweetness) or short (more bitterness) bouts of consumption. Lastly, we will use novel pharmacotherapies to recapitulate VS activity signatures that promote short bouts and test their treatment efficacy in a preclinical model of BED. We are particularly excited about candidate pharmacotherapies with actions in the VS that are known to be safe and well-tolerated in people. MP-10 is a failed schizophrenia drug that activates D2 neurons, Tavapadon is a partial D1 agonist currently in Phase 3 clinical trials for Parkinson's disease, and Liraglutide is a type-II diabetes medication with appetite-suppressing side-effects. Discovering a VS activity signature that disengages dopamine-reinforced behaviour, including eating, and recapitulating this signature using novel pharmacotherapy may rapidly realize efficacious treatment for BED and will inform the treatment of related psychopathologies, like binge alcohol consumption.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
493287
Name
Valyear Milan D
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Leveraging ventral striatal signatures of behavioural disengagement to treat binge-eating disorder
Programtype2
Fellowship Programs
Orgnameinp2
McGill University
Cihramount2
$45,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Addiction; Binge Eating Disorder; Bulimia Nervosa; Calcium Imaging; Dopamine; Feeding; Food Addiction; Optogenetics; Pharmacotherapy; Ventral Striatum
Abstract
People with Binge Eating Disorder (BED), the most common eating disorder, perform longer bouts of eating than is necessary, causing myriad negative health consequences. How the brain controls the durations of bouts of eating is unknown and BED treatments are crude, commonly using antidepressants to address comorbidities rather than BED itself. Dopamine activity in the ventral striatum (VS) powerfully reinforces behaviour, influences food cravings, and is disrupted in BED. If we understood the profiles of activity in dopamine type-1 (D1) and type-2 (D2) neurons within the VS that control eating duration, we could recapitulate these activity signatures to promote healthy eating and treat BED. First, we will allow mice to directly stimulate dopamine activity in the VS and use pharmacology to examine whether D1 or D2 activity disengages this behaviour. Then, we will record the calcium activity of individual cells in the VS while mice consume bittersweet solutions to discover patterns of activity that promote long (more sweetness) or short (more bitterness) bouts of consumption. Lastly, we will use novel pharmacotherapies to recapitulate VS activity signatures that promote short bouts and test their treatment efficacy in a preclinical model of BED. We are particularly excited about candidate pharmacotherapies with actions in the VS that are known to be safe and well-tolerated in people. MP-10 is a failed schizophrenia drug that activates D2 neurons, Tavapadon is a partial D1 agonist currently in Phase 3 clinical trials for Parkinson's disease, and Liraglutide is a type-II diabetes medication with appetite-suppressing side-effects. Discovering a VS activity signature that disengages dopamine-reinforced behaviour, including eating, and recapitulating this signature using novel pharmacotherapy may rapidly realize efficacious treatment for BED and will inform the treatment of related psychopathologies, like binge alcohol consumption.
Competitiondate
202310
Approvedterm2
1 yr 0 mth
Pinamesdelim
Valyear, Milan D
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $45,000~ $0~